BACKGROUND: The purpose of this study was to evaluate the epidemiology and investigate the impact of colonization and pulmonary fungal infections (PFIs). METHODS: In this investigation we performed a retrospective analysis of 55 pediatric lung transplant recipients from 2002 to 2007 at a single institution. Associations between risk factors and time to post-transplant colonization, PFI, and other outcomes were assessed using Cox proportional hazard models. RESULTS: Although 29 patients had positive pre-transplant colonization, 33 (60%) were colonized post-transplant and 20% (11 subjects) developed proven or probable PFI. In a multivariate model, post-transplant fungal colonization was associated with older age (hazard ratio [HR] 2.9, 95% confidence interval [CI] 1.1 to 7.6), cytomegalovirus (CMV) prophylaxis (HR 5.6, 95% CI 1.3 to 24.6) and respiratory viral infection prior to fungal colonization (HR 2.9, 95% CI 1.0 to 8.3). CONCLUSION: Neither fungal colonization nor PFI was associated with the development of chronic allograft rejection or death.
BACKGROUND: The purpose of this study was to evaluate the epidemiology and investigate the impact of colonization and pulmonary fungal infections (PFIs). METHODS: In this investigation we performed a retrospective analysis of 55 pediatric lung transplant recipients from 2002 to 2007 at a single institution. Associations between risk factors and time to post-transplant colonization, PFI, and other outcomes were assessed using Cox proportional hazard models. RESULTS: Although 29 patients had positive pre-transplant colonization, 33 (60%) were colonized post-transplant and 20% (11 subjects) developed proven or probable PFI. In a multivariate model, post-transplant fungal colonization was associated with older age (hazard ratio [HR] 2.9, 95% confidence interval [CI] 1.1 to 7.6), cytomegalovirus (CMV) prophylaxis (HR 5.6, 95% CI 1.3 to 24.6) and respiratory viral infection prior to fungal colonization (HR 2.9, 95% CI 1.0 to 8.3). CONCLUSION: Neither fungal colonization nor PFI was associated with the development of chronic allograft rejection or death.
Authors: I Ruiz; J Gavaldà; V Monforte; O Len; A Román; C Bravo; A Ferrer; L Tenorio; F Román; J Maestre; I Molina; F Morell; A Pahissa Journal: Am J Transplant Date: 2006-01 Impact factor: 8.086
Authors: S A Yousem; G J Berry; P T Cagle; D Chamberlain; A N Husain; R H Hruban; A Marchevsky; N P Ohori; J Ritter; S Stewart; H D Tazelaar Journal: J Heart Lung Transplant Date: 1996-01 Impact factor: 10.247
Authors: S Husain; D L Paterson; S Studer; J Pilewski; M Crespo; D Zaldonis; K Shutt; D L Pakstis; A Zeevi; B Johnson; E J Kwak; K R McCurry Journal: Am J Transplant Date: 2006-12 Impact factor: 8.086
Authors: Frauke Mattner; Iris F Chaberny; H Weissbrodt; S Fischer; P Gastmeier; B Haubitz; J Gottlieb; L Mattner; Martin Strueber Journal: Mycoses Date: 2005 Impact factor: 4.377
Authors: D Metras; L Viard; B Kreitmann; A Riberi; A Pannetier-Mille; O Garbi; J Y Marti; P Geigle Journal: Eur J Cardiothorac Surg Date: 1999-04 Impact factor: 4.191
Authors: R N Husni; S M Gordon; D L Longworth; A Arroliga; P C Stillwell; R K Avery; J R Maurer; A Mehta; T Kirby Journal: Clin Infect Dis Date: 1998-03 Impact factor: 9.079
Authors: J D Cooper; M Billingham; T Egan; M I Hertz; T Higenbottam; J Lynch; J Mauer; I Paradis; G A Patterson; C Smith Journal: J Heart Lung Transplant Date: 1993 Sep-Oct Impact factor: 10.247
Authors: Evan Ammerman; Stuart C Sweet; Matthew Fenchel; Gregory A Storch; Carol Conrad; Don Hayes; Albert Faro; Samuel Goldfarb; Ernestina Melicoff; Marc Schecter; Gary Visner; Nikki M Williams; Lara Danziger-Isakov Journal: Clin Transplant Date: 2017-09-18 Impact factor: 2.863